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Human bocaviruses (HBoVs) are recently described as human emergent viruses, espe-
cially in young children. In this study, we undertook a systematic review and meta-
analysis to estimate their prevalence in Europe. PubMed, Web of Science and Sco-
pus databases were systematically screened for clinical studies, up to October 2020.
Study eligibility criteria were primary full-text articles from clinical studies, con-
ducted using valid screening test methods and published in peer-reviewed journals, in
English or Spanish and fromEuropean countries. The overall pooled prevalence, preva-
lence by country as well as the prevalence of HBoV as a single or co-pathogen were
estimated using a random-effects model. Sub-group and meta-regression analyses
explored potential sources of heterogeneity in the data. A total of 35 studies involving
32,656 subjects from 16 European countries met the inclusion criteria. Heterogene-
ity (I2= 97.0%, p < .01) was seen among studies; HBoV prevalence varied from 2.0 to
45.69% with a pooled estimate of 9.57% (95%CI 7.66-11.91%). The HBoV prevalence
both as a single infection (3.99%; 95%CI 2.99-5.31%) or as co-infection with other
viruses (5.06%; 95%CI 3.88-6.58%) was also analysed. On a geographic level, preva-
lence by country did not show statistical differences, ranging from 3.24% (Greece) to
21.05% (Denmark). An odds ratio analysis was also included in order to evaluate the
relevance of the variable ‘age’ as a risk factor of HBoV infection in children <5 years
old. The OR value of 1.77 (95%CI 1.13-2.77; p < .01) indicated that being <5 years old
is a risk factor forHBoV infection. This study showed thatHBoVhas amoderate preva-
lence among European countries.
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1 INTRODUCTION
The twenty-first century has led to the discovery of several new and
emergent respiratory viruses, being among them human bocaviruses
(HBoVs). HBoVs are recently described viruses belonging to the genus
Bocaparvovirus (family Parvoviridae, subfamily Parvovirinae) which com-
prise four genotypes (HBoV1-4). HBoV1 was first identified in 2005
in nasopharyngeal aspirates from children with respiratory tract infec-
tion (RTI) (Allander et al., 2005). Since 2009, genotypes HBoV2-4 were
subsequently identified (Arthur et al., 2009; Kapoor et al., 2009, 2010).
HBoV are small non-enveloped viruses (∼25 nm in diameter), with
icosahedral T = 1 capsid symmetry and a linear ssDNA genome of
approximately 5 kb in length andnegative- or positive-sense, organized
in three open reading frames (Guido et al., 2016). Intra-species recom-
bination has been shown for all four HBoVs, and a recombination event
between HBoV1 and a common ancestor of HBoV2 and HBoV4 has
been suggested to led to the formation of HBoV3 (Cheng et al., 2011;
Kapoor et al., 2010). HBoVs are commonly detected in children, while
in adults and the elderly, their detection is infrequent (Qiu et al., 2017).
From a clinical perspective, HBoV1 is the most important of HBoVs
and one of the most commonly detected respiratory viruses, causing
mild to severeupper or lowerRTI in children (mainly between6months
and 5-year-old). HBoV1 is most likely transmitted by the respiratory
route and can be detected in very high loads in the respiratory tract
during the acute phase, after which it may persist at low viral loads for
months (Martin et al., 2010; Qiu et al., 2017).
HBoV2-4 are mainly detected in faecal samples, being HBoV2 the
most frequent genotype followed by HBoV1, HBoV3 and HBoV4 (Qiu
et al., 2017). The general lack of HBoV2-4 genotypes in respiratory
samples and their presence in faeces suggest that these genotypes
are enteric and spread most likely via faecal–oral route. However, the
occurrence of HBoVs in faeces is similar among patients with or with-
out symptoms of respiratory or gastrointestinal infection, so the causal
role of HBoV in gastrointestinal disease is still unclear (Arthur et al.,
2009; Kapoor et al., 2009, 2010).
Besides respiratory and stool samples, HBoVs have also been
detected in urine (Wang et al., 2010), saliva (Martin et al., 2009), blood
(Li et al, 2015; Tozer et al., 2009 ), tonsils (Lu et al., 2008), cerebrospinal
fluid (Mitui et al., 2012), as well as in environmental samples like river
water (Hamza et al., 2009), sewage (Iaconelli et al., 2016) and shellfish
(La Rosa et al., 2018). The implications of these non-respiratory find-
ings are uncertain.
Since their discovery in 2005, HBoVs have gained considerable
attention due to its global distribution in clinical samples. The preva-
lence of HBoVs has been reported ranging from 1 to 56.8% of respi-
ratory tract samples and from 1.3 to 63% of stool samples, depend-
ing on the country. Globally, theHBoVs total prevalencewas estimated
around6% (Guido et al., 2016). However, high prevalence does not nec-
essarily mean high clinical relevance, and proving its causative role has
been difficult, in part because the virus is often detected along with
other respiratory and enteric viruses at co-detection rates as high as
75% (Christensen et al., 2010; Guido et al., 2016; Martin et al., 2010).
These facts raise the question about the true contribution and sig-
nificance of HBoV as a causative agent in human infections. In this
study, a systematic review and meta-analysis on the pooled estimates
of theHBoV infectionswere conducted to gain knowledge on the over-
all prevalence of HBoV in Europe, detected both as a single pathogen
or in the presence of other viruses, as well as to determine whether
this prevalence vary across European countries.We also performed an
odds ratio (OR) analysis to determine if age is a risk factor for HBoV
infection.
2 MATERIALS AND METHODS
2.1 Study design and article searching strategy
The protocol of this systematic review andmeta-analysis was designed
according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis Protocols (PRISMA-P 2015) Guidelines (Shamseer
et al., 2015). The literature search strategy, selection of studies, data
extraction and result reporting were also done in accordance with the
PRISMA guidelines (Moher et al., 2009). A comprehensive literature
search was done in PubMed, Web of Science and Scopus using key-
words and Boolean logic operators. The keywords used were: ‘human
bocavirus’, ‘HBoV’, ‘respiratory tract infection’, ‘gastrointestinal tract infec-
tion’, ‘prevalence’ and ‘hospitalized children’. The detailed search strat-
egy is provided in Supporting information. Additionally, related articles
were retrievedmanually fromGoogle Scholar and critically evaluated.
2.2 Eligibility criteria
Only primary full-text articles (clinical studies), from 2005 to October
2020, conducted using valid screening test methods (PCR or ELISA)
andpublished in peer-reviewed journals, in English or Spanish and from
European countries were considered. Studies with unclear epidemio-
logical information (e.g., lacking age range or number of analysed indi-
viduals) or methodological inconsistencies were not included in the
study.
2.3 Article selection and data extraction
All articles were imported into Mendeley Desktop software (version
1.19.4) and duplicated articles were removed. Remaining articles were
later screened independently by three authors (DP, AL and EG) to iden-
tify eligible studies according to the eligibility criteria. After the screen-
ing of published articles for eligibility, relevant data and information
were extracted from each eligible study and curated in a Microsoft
Excel (version 16.43; 2020) sheet including name of the first author,
year of publication, country, detection technique (RT-qPCR, ELISA),
age of the patients, sample type, sample size, number of HBoV positive
cases, number ofHBoVpositive cases as a single virus, number ofHBoV
positive cases in co-detection with other viruses and study population.
Two authors (D.P., A.L.) independently collated data from the eligible
studies and evaluated the data. Any inconsistencies or disagreement
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F IGURE 1 PRISMA flow diagram for the identification and selection of articles for inclusion in the systematic review andmeta-analysis
were discussedwith a third author (J.L.R.) andwas resolved by consen-
sus.
2.4 Statistics and meta-analysis
Datamanipulation andmeta-analysis to calculate the pooled estimates
of HBoV prevalence were done using R software (version 3.6.3) and
its IDE Rstudio software (RStudio Team, Boston, MA; version R v3.6.3)
using ‘readxl’ (version 1.3.1) (Wickham & Bryan, 2019), ‘meta’ (version
4.15-1) (Balduzzi et al., 2019) and ‘metafor’ (version 2.4-0) (Viecht-
bauer, 2010) packages. A random-effects (RE)model (DerSimonian and
Laird method) at 95% CI was used to estimate the pooled prevalence.
The use of RE models is recommended (instead of the fixed-effects
model) when there is a high degree of heterogeneity between stud-
ies, to adjust this observed variability (Borenstein et al., 2009; Veroniki
et al., 2016). The Cochrane’s Q statistic and the I2 index statistic were
calculated for each analysis to check the proportion of the overall vari-
ation that was attributable to the heterogeneity between studies. Its
value can range from0 to100%,whereavalueof>75%represents high
degree of heterogeneity. The sources of heterogeneity were further
analysed using the sensitivity analysis, outlier detection, sub-group
analysis and meta-regression. Egger’s test and Funnel plots were used
to investigate publication bias and small-study effects. Comparative
analyses of theHBoVprevalences among countrieswere conducted by
Kruskal–Wallis non-parametric test. The OR and the 95% confidence
interval (CI) was also calculated for the variable age <5 years old as a
risk factor for the infection with HBoV.
3 RESULTS
3.1 Study selection
A total of 2083 studies were identified from the databases and man-
ual searching. After removing duplicated articles and articles outside
Europe, 118 studies were critically screened by their title and abstract
and 81 studies were identified for full-text evaluation. After apply-
ing the eligibility criteria, 46 studies were excluded due to the lack
of detailed data or their potential for introducing bias. The remaining
35 studies fulfilled the inclusion criteria and were used for the meta-
analysis (Figure 1).
3.2 Descriptive characteristics of included studies
A total of 35 articles were enrolled in the study to be used in this sys-
tematic review and meta-analysis, with a total of 32,656 cases. The
4 POLO ET AL.
sample size across the studies ranged from 32 (Bajolle et al., 2014) to
9098 (Bagasi et al., 2020) samples. Regarding the geographic distribu-
tion of the studies, nine studies were obtained from Italy (Don et al.,
2010; Esposito et al., 2008;Gerna et al., 2007;Guido et al., 2011;Maggi
et al., 2007; Midulla et al., 2010; Nicolai et al. 2017; Pierangeli et al.,
2008; Principi et al., 2015;), four studies from Spain (Calvo et al., 2008,
2016; García-García et al., 2007; Pozo et al., 2007), four studies from
France (Bajolle et al., 2014; Brieu et al., 2008; Foulogne et al., 2006;
Jacques et al., 2008), three studies fromGermany (Kleines et al., 2007;
Volz et al., 2007; Weissbrich et al., 2006), three studies from Finland
(Kantola et al., 2010; Paloniemi et al., 2014; Risku et al., 2012), two
studies from UK (Bagasi et al., 2020; Nawaz et al., 2012), two studies
from Slovenia (Praznik et al., 2018; Ursic et al., 2012) and one study
from Sweden (Allander et al., 2007), Norway (Christensen et al., 2008),
Denmark (von Linstow et al., 2008), Greece (Haidopoulou et al., 2010),
Albania (La Rosa et al., 2016), Bulgaria (Korsun et al., 2019), Belgium
(Verbeke et al., 2019) and Poland (Sobkowiak et al., 2020) (Table 1).
3.3 Meta-regression and sensitivity analysis
A meta-regression analysis was done on the variables ‘year of study’,
‘country’, ‘co-infections’, ‘technique’, ‘HBoV mono-infection’. Only the
variable ‘year of study’ resulted significantly associated with HBoV
pooled prevalence, with a significant regression coefficient of 9.25
(p = .027; SD 0.03). Sensitivity analysis was also performed by remov-
ing a single study from the analysis in order to ensure the stability of
the overall effect estimate. The result indicated that removing a single
study from the analysis did not significantly influence the pooled esti-
mate.
3.4 Publication bias and small study effects
The presence of publication bias was evaluated using funnel plots and
Egger’s test. The regression test for funnel plot asymmetry shows the
symmetry between the studies so we can accept that there is no publi-
cation bias. First, studies’ effect sizes were plotted against their stan-
dard errors and the visual evaluation of the funnel plot indicated no
publication bias as the graph appear symmetrical (Supporting infor-
mation Figure S1). The subjective evidence from the funnel plot was
objectively confirmed using the Egger’s weighted regression statistics.
According to the symmetry assumption, the p-value of .1659 indicates
the absence of small study effects among the included studies.
3.5 Meta-analysis of HBoV prevalence in Europe
HBoV prevalence in Europe among included studies ranged from 2%
in Finland (Kantola et al., 2010) to 46% in Italy (Guido et al., 2011),
although most of the studies ranged between 2 and 22% (Table 1). The
overall pooled prevalence among the total 32,656 cases based on the
REs model was 9.57% (95%CI: 7.66-11.91) with a heterogeneity index
I2 of 97% (95%CI: 95.52-98.40) (p< .001) (Supporting information Fig-
ure S2). However, the occurrence of HBoV as single pathogen decrease
to 3.99% (95% CI: 2.99-5.31) (Figure 2A) while the frequency of co-
detection was 5.06% (95% CI: 3.88-6.58) (Figure 2B). Results of the
prevalence pooled by countries were as follow: Albania (9.15%), Bel-
gium (6.68%), Bulgaria (6.99%), Denmark (21.05%), Finland (9.84%),
France (8.48%), Germany (8.35%), Greece (3.24%), Italy (7.77%), Nor-
way (11.97%), Poland (11.88%), Slovenia (19.87%), Spain (11.60%),
Sweden (18.92%) and UK (3.78%) (Figure 3). Kruskall–Wallis test, per-
formed to compare the prevalence between countries, was not signifi-
cant.
3.6 Sub-group analysis
Since the meta-analysis exhibited a high degree of heterogeneity
(I2 = 97%; p < .001), a sub-group analysis using the variable ‘age’
(younger and older of 5-year-old) as a potential source of heterogene-
ity among the 35 included studies was performed. The sub-group anal-
ysis indicated that the overall prevalence of HBoV slightly increased
among children younger than 5-year-old (9.70%; CI: 7.34-12.73) while
in patients older than 5-year-old was reduced (9.30%; CI: 6.27-13.60).
On the other hand, the heterogeneity was reduced in patients older
than 5-year-old (I2 = 91%; p < .001), indicating that the variable ‘age’
can explain part of the heterogeneity in this group (Supporting infor-
mation Figure S3, Table 2).
3.7 Risk ratio analysis
In order to evaluate the relevance of the variable ‘age’ as a risk fac-
tor for HBoV infection in children <5 years old, we pooled a total of
five studies that indexed the discrete number of positives samples for
HBoV in children under this age and also included a control group. The
analysis showed a RR value of 1.77 (95% CI: 1.13-2.77; p = .01) by a
REmodel, indicating that less than 5 years old is a risk factor for HBoV
infection (Figure 4).
4 DISCUSSION
The emergence of novel respiratory viruses is being of a particular con-
cern during the beginning of this century and it is expected to increase
in the next years. The estimation of an accurate prevalence for these
viral infections is of public health importancebut relies onhugeandepi-
demiologically representative surveys. In the absence of such informa-
tion, this study provides a retrospective systematic review and meta-
analysis for the overall prevalence of HBoV infection in Europe. We
included35studies from16differentEuropeancountries,whichmakes
us think that the data can be reasonably extrapolated to the European
continent.
The rigorous methodological and statistical procedures employed
give robustness to the estimations present here.Nevertheless, findings
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TABLE 1 Characteristics and summary of outcomes from the 35 included studies in this systematic review andmeta-analysis
Authors (Ref) Year Country Na N+b P (%)c
Mono- Inf
(%)d Co-inf (%)e Other virusesf Sampleg
Study
populationh
Foulogne et al. 2006 France 589 26 4.41 17 (65.38) 9 (34.62) RSV, AdV, hMPV NS AH
Weissbrich et al. 2006 Germany 835 87 10.42 53 (60.92) 34 (39.08) RSV, IFV-A, IFV-B, AdV,
HPIV 1, 2, 3
NS AH
Allander et al. 2007 Sweden 259 49 18.92 12 (24.49) 37 (75.51) Yes, not specified NS, SE SA
García-García et al. 2007 Spain 301 49 16.28 13 (20.41) 39 (79.59) RSV, RhV, AdV, hMPV, EV,
HPIV
NS AH
Gerna et al. 2007
‘
Italy 426 42 9.86 16 (30.95) 29 (69.05) RSV, RhV NS, BAL AH
Kleines et al. 2007 Germany 94 12 12.77 7 (58.33) 5 (41.67) RSV NS, BAL AH
Maggi et al. 2007 Italy 284 9 3.17 6 (55.56) 4 (44.44) RhV NS, ST, SE AH
Pozo et al. 2007 Spain 730 115 15.75 49 (35.65) 74 (64.35) RSV, AdV, RhV NS, ST, UR AH
Volz et al. 2007 Germany 389 11 2.83 7 (63.64) 4 (36.36) RSV, NoV NS, SE AH
Brieu et al. 2008 France 507 55 10.85 23 (60.00) 22 (40.00) RSV, hMPV NS AH
Calvo et al. 2008 Spain 710 99 13.94 80 (80.81) 19 (19.19) RSV, AdV, RhV, HPIV, EV NS, BAL AH





Esposito et al. 2008 Italy 1332 99 7.43 49 (49.49) 50 (50.51) RSV, hMPV NS SA
Jacques et al. 2008 France 192 24 12.50 14 (58.33) 10 (41.67) RV, AdV, RSV, RV, HMPV,
IFV-A, EV
NS AH
Pierangeli et al. 2008 Italy 415 34 8.19 13 (38.82) 21 (61.18) RSV NS AH
von Linstow et al. 2008 Denmark 228 48 21.05 21 (43.75) 27 (56.25) RhV, CoVOC43, AdV,
RSV, hMPV, HPIV-1
NS, ST PCS
Midulla et al. 2010 Italy 182 22 12.09 7 (31.82) 15 (68.18) RSV NS AH
Don et al. 2010 Italy 101 12 11.88 7 (66.67) 4 (33.33) RhV, AdV, hMPV BLO, NS AH
Haidopoulou et al. 2010 Greece 370 12 3.24 8 (66.67) 4 (33.33) IFV-A, CoV-OC43 NS AH
Kantola et al. 2010 Finland 250 5 2.00 NA NA not specified ST SA
Guido et al. 2011 Italy 116 53 45.69 27 (50.94) 26 (49.06) hMPV, IFV-A, IFV-B NS SA
Nawaz et al. 2012 UK 4380 324 7.40 175 (54.00) 149 (46.00) Yes, not specified ST CCS
Risku et al. 2012 Finland 990 92 9.29 22 (23.91) 70 (76.09) RV, NoV, SaV, AdV, AiV,
CoV
ST SA
Uršič et al. 2012 Slovenia 760 158 20.79 66 (37.97) 98 (62.03) RSV, RhV, IFV-A, CoV,
AdV, HPIV-3, hMPV
NS, BAL AH
Bajolle et al. 2014 France 32 7 21.88 6 (85.71) 1 (14.29) Yes, not specified NS, SE AH
Paloniemi et al. 2014 Finland 955 119 12.46 NA NA RV, NoV, AsV NS, ST SA
Principi et al. 2015 Italy 1823 104 5.70 57 (54.81) 47 (45.19) EV, RV and RSV NS SA
La Rosa et al. 2016 Albania 142 13 9.15 0 (0.00) 13 (100.00) RhV, AdV ST AH
Calvo et al. 2016 Spain 3275 319 9.74 80 (25.08) 239 (74.92) RSV, RhV, AdV NS AH
Nicolai et al. 2017 Italy 273 10 3.66 6 (60.00) 4 (40.00) hMPV, RV, RSV NS AH
Korsun et al. 2019 Bulgaria 515 36 6.99 20 (55.56) 16 (44.44) RSV, HPIV-1, HPIV-3, RV,
AdV, RhV
NS SA
Praznik et al. 2018 Slovenia 473 87 18.39 NA NA not specified NS AH
Verbeke et al. 2019 Belgium 1153 77 6.68 6 (6.49) 72 (93.51) RV, AdV NS AH
(Continues)
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TABLE 1 (Continued)
Authors (Ref) Year Country Na N+b P (%)c
Mono- Inf
(%)d Co-inf (%)e Other virusesf Sampleg
Study
populationh
Bagasi et al. 2020 UK 9098 185 2.03 43 (23.24) 142 (76.76) Yes, not specified NS, BAL, SPU RCS
Sobkowiak et al. 2020 Poland 101 12 11.88 5 (41.67) 7 (58.33) Yes, not specified NS AH
Total 32,656 2451 9.57 9255 (45.90) 1326 (54.10)
aN, total cases involved in each study.
bN+, number of HBoV positive cases.
cP (%), HBoV prevalence for each study calculated as the ratio betweenN andN+.
dMono-inf (%), number (percentage) of positive cases detecting HBoV as a single virus.
eCo-inf (%), number (percentage) of positive cases detecting HBoV alongwith other viruses.
fOther viruses: AiV, aichivirus; AsV, astrovirus; AdV, adenovirus; EV, CoV, coronavirus; CMV, cytomegalovirus; enterovirus; hMPV, humanmetapneumovirus;
HPIV, human parainfluenza virus type 1, 2 and 3; IFV-A, influenza virus type A; IFV-B, influenza virus type B; NoV, norovirus; RV, rotavirus; RhV, rhinovirus;
SaV, sapovirus; RSV, respiratory sincitial virus.
gSample type analyzed: NS, nasopharyngeal sample; SE, serum; BAL, bronchoalveolar lavage, ST, stool; UR, urine; BLO, boold; SPU, sputum.
hAH, admitted to hospital; SA, seeking assistance; PCS, prospective cohort study; CCS, case control study; RCS, retrospective cohort study.
F IGURE 2 Forest plot showing the prevalence of HBoV in Europe as a single infection (A) and co-infection (B) from the 35 included studies and
using random-effects model (DLmethod). The study-specific prevalence and 95%CIs are denoted by blue boxes and black lines. The size of squares
proportional to the weight assigned to the study in themeta-analysis. The overall estimate is represented by the diamond, where diamondwidth
corresponds to 95%CI bounds. Box and diamond heights are inversely proportional to precision of the proportion estimate
should be interpreted considering some limitations, mainly related to
the way the data are presented in the included studies.
The inclusion of the number of total cases and positive cases for
each group of age is crucial to better exploit the results and for a
meta-analysis of prevalence. However, we found that age groupingwas
highly variable in published reports, which made difficult to sub-group
study populations into finite age groups and the assignment of their
respective prevalence.
Ahighdegreeof heterogeneity between studieswas founded,which
is very common in meta-analyses of prevalence (Veroniki et al., 2016).
In this regard, sub-group analysis was undertook to identify sources
of heterogeneity, however, the source of this heterogeneity was not
found and some characteristics that may further explain it were not
reported in the original studies. For instance, the seasonal occurrence
of HBoV is still a subject of debate. Although HBoV infection is diag-
nosed throughout the year and no clear seasonality has been observed
in several epidemiological studies (Christensen et al., 2010; Martin
et al., 2015), there are increasing evidences suggesting the higher fre-
quencies of the viral infection in the cold months of the year. Most of
the studies included in this review reported a HBoV seasonality during
fall andwinter. This could be a factor contributing to the heterogeneity
among the studies and should be considered in the meta-analysis.
However, most of these studies did not included detailed informa-
tion about the distribution of the HBoV infections by months, so a
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F IGURE 3 Box-plot diagram showing the pooled prevalence of HBoV by each country represented in themeta-analysis
TABLE 2 Pooled prevalence andmeta-analysis statistics of HBoV in Europe using the included studies
Group Prevalence (95%CI) I2 (95%CI) t2 (95%CI) p-value (p< .05)
Overall 9.57 (7.66-11.91) 96.77 (95.52-98.40) 0.50 (0.36-1.03) 1.00E-04
<5 years old 9.70 (7.34-12.73) 98.00 (95.20-98.10) 0.52 (0.4-1.00) 1.00E-04
>5 years old 9.30 (6.27-13.60) 91.00 (90.12-95.42) 0.52 (0.4-1.00) 1.00E-04
HBoVmono-detection 3.99 (2.99-5.31) 94.40 (93.00-95.50) 0.65 (0.40-1.36) 1.00E-04
HBoV co-detection 5.06 (3.89-6.58) 95.30 (94.20-96.20) 0.56 (0.33-1.13) 1.00E-04
seasonality analysis could not be performed. On the other hand, per-
forming sub-group and regression analysis, the variable ‘age < 5 years
old’ was identified as the cause of part of the heterogeneity. However,
other part of the heterogeneity could not be completely eliminated
possibly due to clinical and methodological diversity of the included
studies or to statistical heterogeneity.
In this study, different countrieswere variably represented, some of
them with only one study. Geographical location has been previously
reported as variable between countries and may also be one of the
factors contributing to the heterogeneity (De et al., 2017). Although
this may weaken to some extent the generalizability of our findings for
every single country, themeta-regressionmodel did not find any statis-
tical difference. In this sense, more epidemiological studies are needed
in these regions. For 2011 and2018, the prevalence by year is only rep-
resented by a single study. However, more important than the num-
ber of studies is the cohort involved. In that sense, the year 2011 has
included an extremely low number of cases hampering the accurate
estimation of the prevalence for that year.
The study presented here estimates the overall prevalence for
HBoV infection without distinguishing between genotypes. Previous
F IGURE 4 Forest plot on analysis on odd ratio (OR) and 95% confidence interval (CI) according to HBoV prevalence using the variable ‘age’
younger than 5-year-old
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studies have reported that the genotypes of HBoVs most frequently
detected are, in descending order, HBoV1, HBoV2, HBoV3 and HBoV4
(Söderlund-Venermo, 2019 ). Among the included studies, only a few
differentiate between the four HBoV genotypes, so the detection
rate for each genotype could not be reported. In this respect, test-
ing simultaneously at least HBoV1 and HBoV2, the most frequent
genotypes according to literature, would allow to obtain a better
analysis of the prevalence and the epidemiology of HBoV (Kantola
et al., 2010).
Besides these limitations, we estimated a pooled overall prevalence
of HBoV of 9.57%. This relatively high prevalence is in accordance
with previous studies. Guido et al. (2016) estimated a global HBoV
prevalence of 6.3 and 5.9% in respiratory and gastrointestinal infec-
tion, respectively. Other large-scale studies have detected HBoV from
9 to 19.3% of all samples (Bronzel et al., 2008; Christensen et al., 2010;
Franz et al., 2010;Martin et al., 2010). The absence of statistical differ-
ences for the pooled prevalence by country suggests a homogeneous
distribution of HBoV among European countries.
One important strength of the present systematic review andmeta-
analysis is that HBoV prevalence as mono-infection and co-infection
were analysed separately. This is important because multiple viral
detections are common in young children and HBoV is frequently
detected together with other respiratory and enteric viruses both in
respiratory and gastrointestinal samples from symptomatic or asymp-
tomatic infants (Christensen et al., 2010; Martin et al., 2010; Schild-
gen et al., 2008). Even in respiratory samples containing actively tran-
scribingHBoV1, other viruses have been detected in almost 60%of the
cases (Christensen et al., 2013).
Guido et al. (2016) estimated the rate of HBoV co-infections with
other viruses at 52.4% (respiratory infections) and 46.7% (gastroin-
testinal infections) and HBoV is typically found as the second or third
most commonly detected virus, after RSV and RhV (Christensen et al.,
2010;Martin et al., 2010). In thepresent study, theoverall co-detection
rate of HBoV with other viruses was 54.1% (Table 1). The studies
included here also reported RSV, AdV and RhV as the other viruses
more commonly detected along with HBoV. These facts strongly sug-
gest that HBoV is an important respiratory pathogen in children but
also that it may exist in the respiratory or gastrointestinal tract as a
bystander virus.
Some explanations for these high co-detection rates are the pro-
longed shedding of HBoV, that can last for months after the primary
infection (Martin et al., 2010, 2015; von Linstow et al., 2008; Wagner
et al., 2016) and the fact that children can have up to ten respiratory
infections per year (Kusel et al., 2006). Other questions that remain
poorly understood arewhetherHBoV1 has amore active or synergetic
role in multiple respiratory infections and if it can establish latency
by integration into the host cell genome or as an episome (Schildgen
et al., 2012). Until the mechanisms of HBoV persistency, reactivation
and reinfection are unravelled, occurrence values as a single- and co-
pathogen should be reported. In this regard, this study adds valuable
data for this porpoise.
At the time of this writing, COVID-19 pandemic continues to run its
course. In this new context, viral prevalence studies conducted before
the onset of the pandemic will be very useful to evaluate how the
control measures against SARS-CoV-2 (wearing masks, hand hygiene,
social distancing, lockdowns, travel restrictions) can impact the preva-
lence of other respiratory viruses.
Conducting a retrospective epidemiological study, Chiu et al. (2020)
found a significant decrease in cases of influenza, enterovirus and all-
cause pneumonia during the COVID-19 pandemic (Chiu et al., 2020).
In this sense, we provide here a pre-COVID-19 snapshot of the HBoV
prevalence in Europe. Further studies are warranted to evaluate if
HBoV prevalence, as the other emergent respiratory viruses, decrease
as a result of the implemented measures against SARS-CoV-2 or
if other factors, such as virus competition, may contribute as well
(Latorre-Margalef et al., 2017; Lin et al., 2020; Pinky & Dobrovolny,
2016; Trinh & Zeng, 2017).
5 CONCLUSIONS
In summary, this systematic review and meta-analysis provides a clear
summary of the existing knowledge on the European prevalence of
HBoV infection. Data presented here show that HBoV infection is rela-
tively frequent in children admitted to hospital and should be incorpo-
rated as part of the standard diagnostic panels, especially for children
under 5 years old. This meta-analysis also emphasizes the importance
of analysing thepresenceof this virusbothasa singlepathogenor in co-
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